JP2021519312A5 - - Google Patents

Info

Publication number
JP2021519312A5
JP2021519312A5 JP2020551973A JP2020551973A JP2021519312A5 JP 2021519312 A5 JP2021519312 A5 JP 2021519312A5 JP 2020551973 A JP2020551973 A JP 2020551973A JP 2020551973 A JP2020551973 A JP 2020551973A JP 2021519312 A5 JP2021519312 A5 JP 2021519312A5
Authority
JP
Japan
Prior art keywords
substituted
optionally substituted
nhc
group
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023457 external-priority patent/WO2019190885A1/en
Publication of JP2021519312A publication Critical patent/JP2021519312A/ja
Publication of JP2021519312A5 publication Critical patent/JP2021519312A5/ja
Pending legal-status Critical Current

Links

JP2020551973A 2018-03-28 2019-03-21 カルパインモジュレーター及びその治療的使用 Pending JP2021519312A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649451P 2018-03-28 2018-03-28
US62/649,451 2018-03-28
PCT/US2019/023457 WO2019190885A1 (en) 2018-03-28 2019-03-21 Calpain modulators and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2021519312A JP2021519312A (ja) 2021-08-10
JP2021519312A5 true JP2021519312A5 (cg-RX-API-DMAC7.html) 2022-03-03

Family

ID=68060735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551973A Pending JP2021519312A (ja) 2018-03-28 2019-03-21 カルパインモジュレーター及びその治療的使用

Country Status (20)

Country Link
US (1) US20210009564A1 (cg-RX-API-DMAC7.html)
EP (1) EP3774737A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021519312A (cg-RX-API-DMAC7.html)
KR (1) KR20200139702A (cg-RX-API-DMAC7.html)
CN (1) CN112204014A (cg-RX-API-DMAC7.html)
AR (1) AR115303A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019242387A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020019560A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095164A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002496A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020012359A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP20068210A (cg-RX-API-DMAC7.html)
IL (1) IL277548A (cg-RX-API-DMAC7.html)
MX (1) MX2020010033A (cg-RX-API-DMAC7.html)
PE (1) PE20212111A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551555A1 (cg-RX-API-DMAC7.html)
RU (1) RU2020130022A (cg-RX-API-DMAC7.html)
SG (1) SG11202008750XA (cg-RX-API-DMAC7.html)
TW (1) TW202003472A (cg-RX-API-DMAC7.html)
WO (1) WO2019190885A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US10934261B2 (en) * 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CN112166111A (zh) * 2018-03-28 2021-01-01 布莱德治疗公司 治疗纤维化疾病的方法
EP3820864A4 (en) * 2018-06-28 2022-03-30 Blade Therapeutics, Inc. METHOD OF TREATMENT OF HEPATIC FIBROSIS USING CALPAIN INHIBITORS
BR112022025037A2 (pt) 2020-06-10 2023-02-14 Aligos Therapeutics Inc Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
AU4544993A (en) * 1992-06-24 1994-01-24 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
DE19642591A1 (de) * 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
DE19817459A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
HK1039110A1 (zh) * 1999-03-15 2002-04-12 Axys Pharmaceuticals, Inc. 以新颖的合成物及组分作为蛋白酶抑制剂
WO2005000793A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. 2位置換シクロアルキルカルボン酸誘導体
EP1493739A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CL2007003879A1 (es) * 2006-12-29 2008-07-04 Basf Ag Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.
TWI519530B (zh) * 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途
US8236798B2 (en) * 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US9051304B2 (en) * 2009-12-22 2015-06-09 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors V
MX2013006419A (es) * 2010-12-09 2013-12-16 Abbvie Inc Compuestos carboxamida y su uso como inhibidores de calpaina v.
EP3107952B1 (en) * 2014-02-19 2018-09-26 ETH Zurich Method for the generation of chemical libraries
AU2017290705B2 (en) * 2016-06-29 2021-08-26 Rascal Therapeutics, Inc. Compounds and compositions for the treatment of cancer
US10934261B2 (en) * 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CN112166111A (zh) * 2018-03-28 2021-01-01 布莱德治疗公司 治疗纤维化疾病的方法

Similar Documents

Publication Publication Date Title
JP2021519764A5 (cg-RX-API-DMAC7.html)
JP2020500207A5 (cg-RX-API-DMAC7.html)
JP2023544476A5 (cg-RX-API-DMAC7.html)
JP2012509891A5 (cg-RX-API-DMAC7.html)
JP2014531434A5 (cg-RX-API-DMAC7.html)
JP2024514010A5 (cg-RX-API-DMAC7.html)
JP2008510691A5 (cg-RX-API-DMAC7.html)
WO2006098918B1 (en) Substituted gamma lactams as therapeutic agents
RU2020130012A (ru) Способ лечения фиброзного заболевания
JP2014502979A5 (cg-RX-API-DMAC7.html)
JP2002528490A5 (cg-RX-API-DMAC7.html)
JP2009534405A5 (cg-RX-API-DMAC7.html)
JP2015164972A5 (cg-RX-API-DMAC7.html)
TW201010990A (en) New combination-408
JP2011527675A5 (cg-RX-API-DMAC7.html)
RU2014106999A (ru) Замещенные производные 3-тиазолоаминопропионовой кислоты и их применение в качестве фармацевтических препаратов
RU2468793C2 (ru) Композиции на основе соединений 2-амино-1,3-пропандиола
JP2024517769A5 (cg-RX-API-DMAC7.html)
KR20010101922A (ko) 고혈압 치료를 위한 약제학적 조성물
RU2006124856A (ru) Гидронопольные производные в качестве агонистов по отношению к orl1 рецепторам человека
JP2013544786A5 (cg-RX-API-DMAC7.html)
US20100311756A1 (en) Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
JP4011114B2 (ja) 脳浮腫抑制剤
RU2005137184A (ru) Новые производные тропана
WO2012004287A1 (en) 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors